Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10929
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSiderov, Jimen
dc.contributor.authorKirsa, Sueen
dc.contributor.authorMcLauchlan, Roberten
dc.date.accessioned2015-05-16T00:30:24Z
dc.date.available2015-05-16T00:30:24Z
dc.date.issued2009-12-04en
dc.identifier.citationJournal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners 2009; 16(1): 19-25en
dc.identifier.govdoc19965949en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/10929en
dc.description.abstractThe potential for staff exposure to antineoplastic agents exists in the workplace despite current recommended safe handling procedures. Reliance on cytotoxic drug safety cabinets (CDSC) to provide total protection from exposure to hazardous drugs is insufficient. Preventing workplace contamination is the best strategy to minimise exposure. PhaSeal is a commercially available system for ensuring the leak-free transfer of hazardous drugs, fitting both the NIOSH and ISOPP definitions of a closed system. To date, there have been no published studies examining the use of a closed system drug transfer device (PhaSeal) under Australian conditions.The purpose of this study is to determine the impact of a closed system drug transfer device on cytotoxic surface contamination in the cytotoxic preparation areas of two Australian metropolitan public hospitals.This was a pre- and post-intervention study in which chemical contamination was tested at baseline then at five and 12 months after the introduction of the a closed system drug transfer device. Cyclophosphamide was used as a surrogate marker for all cytotoxic drugs. Surface wipe sampling was performed at specified sites within the cytotoxic suite using a standardized technique. Commercial products of cyclophosphamide were also sampled.After five months, contamination was reduced in 13 of the 22 sites sampled (59%), with four of these samples showing undetectable levels of contamination. Two other site samples (9%) remained unchanged. The total contamination of surfaces tested was reduced by 24%. After five months hospital 1 withdrew from the study. After 12 months, surface contamination was reduced in 75% of sample sites. The total contamination of surfaces tested was reduced by 68%. The wipes of the external surface of commercial products detected cyclophosphamide contamination.When used inside a CDSC, the closed system drug transfer device PhaSeal further reduces surface contamination, in some instances to undetectable levels.en
dc.language.isoenen
dc.subject.otherAntineoplastic Agents.analysis.poisoningen
dc.subject.otherAustraliaen
dc.subject.otherCyclophosphamide.analysis.poisoningen
dc.subject.otherDrug Compounding.instrumentationen
dc.subject.otherDrug Packaging.statistics & numerical dataen
dc.subject.otherEnvironmental Monitoringen
dc.subject.otherEquipment Designen
dc.subject.otherEquipment and Supplies, Hospital.statistics & numerical dataen
dc.subject.otherHazardous Substances.analysis.poisoningen
dc.subject.otherHealth Facility Environment.statistics & numerical dataen
dc.subject.otherHospitals, Publicen
dc.subject.otherHumansen
dc.subject.otherOccupational Exposure.prevention & controlen
dc.subject.otherPharmacy Service, Hospital.methodsen
dc.subject.otherSafety Management.methodsen
dc.subject.otherSurface Propertiesen
dc.subject.otherTime Factorsen
dc.subject.otherWorkplace.statistics & numerical dataen
dc.titleReducing workplace cytotoxic surface contamination using a closed-system drug transfer device.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitionersen
dc.identifier.affiliationPharmacy Department, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.doi10.1177/1078155209352543en
dc.description.pages19-25en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/19965949en
dc.type.austinJournal Articleen
local.name.researcherSiderov, Jim
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.grantfulltextnone-
item.languageiso639-1en-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

64
checked on Dec 27, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.